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ABSTRACT (216 words) 43 
Human immunodeficiency virus type-1 (HIV-1) infection is associated with aberrant immune 44 
activation, however, most model systems for HIV-1 have been used during established infection. 45 
Here, we utilize ultra-sensitive HIV-1 quantification to delineate early events during the HIV-1 46 
eclipse, burst and chronic phases of HIV-1 infection in humanized mice. We show that very early in 47 
infection, HIV-1 suppresses peripheral type I interferon (IFN) and interferon-stimulated gene (ISG) 48 
responses, including the HIV-1 restriction factor IFI44. At the peak of innate immune activation, 49 
prior to CD4 T cell loss, HIV-1 infection differentially affects peripheral and lymphoid TLR 50 
expression profiles in T cells and macrophages. This results in a trend towards an altered activation 51 
of NFB, TBK1 and IRF3. The subsequent type I and III IFN responses result in preferential 52 
induction of peripheral ISG responses. Following this initial innate immune activation, peripheral 53 
expression of the HIV-1 restriction factor SAMHD1 returns to levels below those observed in 54 
uninfected mice, suggesting that HIV-1 interferes with their basal expression. However, peripheral 55 
cells, still retain their responsiveness to exogenous type I IFN, whereas splenic cells show a 56 
reduction in select ISG in response to IFN. This demonstrates the highly dynamic nature of very 57 
early HIV-1 infection and suggests that blocks to the induction of HIV-1 restriction factors 58 
contribute to the establishment of viral persistence.  59 
KEYWORDS: HIV-1, Innate immune activation, humanized mouse 60 
 61 
IMPORTANCE 62 
Human immunodeficiency virus (HIV)-1 infection is restricted to humans and some non-human 63 
primates (e.g. chimpanzee, gorilla). Alternative model systems based on SIV infection of macaques 64 
are available but do not recapitulate all aspects of HIV-1 infection and disease. Humanized mice, 65 
which contain a human immune system, can be used to study HIV-1 but only limited information 66 
on early events and immune responses are available to date. Here, we describe very early immune 67 
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we show that HIV-1 infection interacts differently with innate immune responses in blood and 69 
lymphoid organs. 70 
 71 
BACKGROUND 72 
More than 37 million people are currently infected with the human immunodeficiency virus (HIV) 73 
(1). Since HIV-1 stably integrates into the host cell genome of CD4 T cells, no curative therapies 74 
are currently available (2). The narrow species tropism of HIV-1 limits natural infection to humans, 75 
mainly due to incompatibility of host factors and the presence of restriction factors in non-human 76 
cells (3, 4). Even though surrogate model systems are available (e.g. simian immunodeficiency 77 
virus (SIVmac)), these do not recapitulate all the complex host/pathogen interactions evolved by 78 
HIV-1, mostly because they present pre-adaptation strains (i.e. SIVcpz or SIVsm) or HIV-2 79 
progenitors (5, 6). Additionally, SIV and HIV-2 encode an additional accessory protein, Vpx, which 80 
alters disease progression by promoting replication in myeloid cells by blocking the action of the 81 
restriction factor SAM domain and HD domain-containing protein (SAMHD)-1 (7, 8). Furthermore, 82 
in vitro models of HIV-1 persistence in T cells generally require pre-activation of the cells, which 83 
results in their proliferation and altered phenotype. This is in stark contrast to infection in vivo, 84 
where any cellular activation is driven by endogenous processes (9). Even though more 85 
physiological model systems have been developed, including ex-vivo tissue explant models (10, 11) 86 
or cytokine-driven models of HIV-1 latency (12, 13), they often rely on extensive manipulation of 87 
natural physiology, are often challenging to accurately control, and have not yet been demonstrated 88 
to be equivalent to naturally infected cells. 89 
Humanized mice have been developed to bridge this gap, facilitating HIV-1 infection using human 90 
cells in vivo (14). These models largely rely on the ability of human hematopoietic stem cells (HSC) 91 
to utilize the murine bone marrow stem cell niche to reconstitute highly immunodeficient mice with 92 
all major human hematopoietic lineages (15). Even though advanced model systems incorporating 93 
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fetal tissue as well as ethical considerations makes human HSC-engrafted humanized mice the most 95 
widely used and tractable model (15). Even though many of the humanized mouse models have 96 
been used to study HIV-1 infection, currently, no data are available on very early events in the path 97 
to HIV-1 persistence. In addition, early innate immune activation by HIV-1 through type I IFN is 98 
still poorly understood and even less is known in regard to the role of type III IFN in HIV-1 99 
infection. Furthermore, it remains unclear to what extent HIV-1 infection activates (17-19) or 100 
interferes with (20-22) innate immune activation and IFN-based signaling. Even though many ISGs 101 
with antiretroviral activity have been described (3, 23), it remains unclear, to what extent these are 102 
present, induced, repressed or evaded during HIV-1 infection in vivo. 103 
Here, we demonstrate that ultrasensitive detection can be used to distinguish very early eclipse and 104 
burst phases preceding the onset of CD4 T cell loss in humanized mice. These phases give clear 105 
insight into the differential innate immune activation stages involved in establishing HIV-1 106 
persistence as well as illustrating how HIV-1 subverts host efforts to restrict infection. This offers 107 
valuable insight into how HIV-1 interacts with the innate immune system early during infection and 108 
explains why common IFN-stimulated HIV-1 restriction factors may be limited in their capacity to 109 
control infection. 110 
METHODS 111 





/SzJ (NRG) mice were obtained from The Jackson Laboratory and 113 
housed and bred at Imperial College London CBS animal facility. Human CD34+ hematopoietic 114 
stem cells (HSC) were isolated from human fetal livers as previously described (24). Less than 4-115 
day-old NRG mice were sublethally irradiated with 100cGy and 4 hours later were intrahepatically 116 
injected with 1x10
5
 purified CD34+ HSC’s. Each experimental cohort was designed with groups 117 
comprising equal engraftment, gender and more than one HSC donor (Table 1). 118 
 119 
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Wild type NL4.3 BaL was generated via transfection in 293T cells then purified on a 20% sucrose 121 
cushion prior to injection as previously described (25). Humanized mice cohorts were generated 122 
based on equal numbers from different HSC donors, engraftment levels, age and sex prior to 123 
infection. Humanized mice were intravenously injected with 2.1IU of reverse transcriptase, as 124 
measured by SG-PERT as previously described (26) and mock mice were subsequently injected 125 
with an equal volume of vehicle. For the IFN treated cohorts, HIV-1-infected humanized mice, 126 
which displayed stable viraemia, were intraperitoneally injected with 1000IU/g body weight IFN2 127 
(Invitrogen, Paisley, UK) daily for 5 days and then blood and tissues were immediately harvested. 128 
 129 
Isolation of leukocytes from murine tissues  130 
Murine peripheral blood was isolated longitudinally using tail-vein bleeding. Peripheral blood 131 
mononuclear cells were isolated from whole blood using murine red blood cell lysis buffer (Alfa 132 
Aesar, MA, USA) according to the manufacturer’s protocol. Fresh tissue isolated from humanized 133 
mice was washed in PBS and digested using 0.1% w/v collagenase digestion buffer for 30 minutes 134 
at 37C. The digested tissue was then homogenized through a 70uM cell strainer and loaded onto a 135 
Ficoll gradient according to the manufacturer’s protocol and the leukocyte ‘buffy’ layer was washed 136 
in PBS and stained for flow cytometry.  137 
 138 
Isolation of RNA from peripheral blood mononuclear cells and splenic tissue 139 
Fresh splenic tissue was harvested from humanized mice and directly stored in RNAlater 140 
stabilization solution (Life Technologies, Carlsbad, CA, USA) and frozen at -80C. Upon RNA 141 
extraction, the samples were thawed and resuspended in the appropriate amount of RLT buffer 142 
containing β-mercaptoethanol according to the weight of the tissue or cell number. The tissue was 143 
then processed using the TissueLyser LT (Qiagen, Manchester, UK) for 5 minutes at maximum 144 
speed. The RNA was processed using Qiashredder columns (Qiagen) followed by direct RNA 145 
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 147 
Flow cytometry analysis 148 
To evaluate engraftment, 50uL of whole blood was collected from a superficial tail vein 12 weeks 149 
following intrahepatic injection and PBMC’s extracted as previously described. The isolated cells 150 
were then stained using anti-mouse CD45-BV605 (BD Bioscience, NJ, USA) and anti-human 151 
CD45-APC (BD) and engraftment measured by the number of human CD45+ cells in the total 152 
leukocyte population.  153 
Evaluation of human cell populations during both reconstitution analysis in organs and HIV-1 154 
infection studies were performed as described above and staining also included anti-human CD3-155 
PerCP Cy5.5 (BD), anti-human CD4-APC-H7 (BD), anti-human CD8-AF700 (BD), anti-human 156 
CD14-BV510 (BD), anti-human CD19-PE (BD), anti-human CD11b-BV421 (BD), anti-human 157 
IFNAR1-PerCP (Novus, Manchester, UK), anti-human IL28RA-PE (Biolegend, CA, USA), anti-158 
human BST2 (BioLegend) and the Live/Dead Fixable Dead cell staining (Life Technologies). 159 
Additionally, intracellular staining was performed using the BD Cytofix/Cytoperm solution kit 160 
(BD) following the manufacturer’s protocol using the following antibodies; KC57-p24 (Beckman 161 
Coulter, CA, USA), anti-human TLR3-APC (Miltenyi, Bergisch Gladbach, Germany), anti-human 162 
TLR7-Alexa405 (R&D Systems, MN, USA), anti-human TLR8-Alexa350 (R&D) and anti-human 163 
TLR9-FITC (Abcam, Cambridge, UK). For absolute cell counts, CountBright Absolute Counting 164 
beads for flow cytometry (ThermoFisher MA, USA) were added to each sample according to the 165 
manufacturer’s protocol. All data was analysed using FlowJo software. 166 
 167 
Phosflow analysis of protein phosphorylation 168 
Cells isolated from humanized mice were prepared for flow cytometry as described above and 169 
stained with the following extracellular markers; anti-mouse CD45-BV605 (BD), anti-human 170 
CD45-APC (BD), anti-human CD3-APC-eFluor780 (ThermoFisher), anti-human CD8-AF700 171 
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minutes. Following this, cells were permeabilized with Permeabilisation buffer III (BD) for 30 173 
minutes at 4C and stained with the following phosflow antibodies; anti-human pSTAT1-BV421 174 
(BD), anti-human pp65-PerCP eFluor710 (Life Technologies), anti-human pIRF3 S396-PE (Cell 175 
Signalling, MA, USA) and anti-human pTBK-1 (Cell Signalling). 176 
 177 
HIV-1 ultra-sensitive RNA quantification 178 
Total RNA was isolated from <50uL murine plasma-EDTA using the QIAmp viral RNA isolation 179 
kit (Qiagen) according to the manufacturer’s protocol. In the first round, extracts were amplified 180 
using a semi-nested RT-PCR with a limited cycle number using the Superscript III One-Step RT-181 
PCR system (Invitrogen) with primers (SID1: 5’-AAGACAGCAGTACAAATGGCAGT-3’ and 182 
SID2: 5’-TACTGCCCCTTCACCTTTCCA-3’) targeting the HIV-1 integrase genomic region. The 183 
internal control RNA is a transcript of the integrase gene with the probe-binding region containing a 184 
randomized sequence of 25 nucleotides. The second round uses the subsequent DNA product from 185 
the semi-nested RT-PCR as template for the qPCR and HIV copies detected using the QuantiTect 186 
Probe PCR kit (Qiagen) using the following primers and probes (SID2, SID3: 5’-187 
CAATTTTAAAAGAAAAGGGGGGATT-3’, HIV-1 probe: 5’-FAM–188 
CGGGTTTATTACAGGGACAGCAGA–TAMRA-3’ and internal control probe: 5’-VIC–189 
CTGGGTAGAGTAGTCACAGAATGCG– BHQ-3’). 190 
 191 
Gene expression analysis 192 
Isolated RNA extracted from cells or tissue was converted into cDNA using High capacity cDNA 193 
Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) following the manufacturer’s 194 
protocol. Quantification of human IFN, IFN, IFN3 and IFN1 and ISG expression SAMHD1 195 
(5’-TCACAGGCGCATTACTGCC-3’, 5’-GGATTTGAACCAATCGCTGGA-3’), myxovirus 196 
resistance protein (MX)-1, MX2 (5’- CAGCCACCACCAGGAAACA-3’, 5’- 197 
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PCR mastermix (Life Technologies) on the ViiA™ 7 Real-Time PCR System instrument 199 
(Applied Biosystems) using previously described primer sequences (27). Subsequent mRNA 200 
levels were normalized to GAPDH (5’-AGGGCTGCTTTTAACTCTGGT-3’, 5’-201 
CCCCACTTGATTTTGGAGGGA-3’) expression. All primers were generated through Life 202 
Technologies. 203 
 204 
Statistical analysis  205 
All statistical analyses were performed using GraphPad Prism v6.0 and data were evaluated for 206 
statistical significance between experimental cohorts and conditions using one phase exponential 207 
decay with least squares test, ordinary One-way ANOVA with Bonferroni’s multiple comparison 208 
test. For the comparison of mock-infected with HIV-1-infected animals, the median-based unpaired 209 
Mann-Whitney test was performed with Bonferroni corrections. In contrast, a comparison of the 210 
same HIV-1 infected humanized mice at different time-points was analysed using the median-based 211 
paired Wilcoxon matched-pairs ranked sign test with Bonferroni corrections.  For each statistical 212 
analysis, a p value of <0.05 was considered significant. 213 
 214 
Safety/Biosecurity 215 
All work with infectious agents was conducted in biosafety level 3 facilities, approved by the 216 
Health and Safety Executive of the UK and in accordance with local rules, at Imperial College 217 
London, UK. 218 
 219 
Statement on animal ethics 220 
All work was approved by the local genetic manipulation (GM) safety committee of Imperial 221 
College London, St. Mary’s Campus (centre number GM77), and the Health and Safety Executive 222 
of the United Kingdom and carried out in accordance with the approved guidelines. All animal 223 
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Office License, PPL 70/8219 in accordance with the approved guidelines, under the Animals 225 
(Scientific Procedures) Act 1986 (ASPA). 226 
 227 
RESULTS 228 
HIV-1 infection exhibits a multiphasic kinetic, stabilizing after three weeks 229 
Despite many studies utilizing humanized mice to model HIV-1 infection (15), little information 230 
was available on very early virological and immunological events following infection. The 231 
generation of humanized mice by intrahepatic injection of HSC into sub-lethally irradiated NRG 232 
mice resulted in multilineage engraftment of human immune cells in all major organs within three 233 














cytotoxic T cells, were present in physiological frequencies and, despite their lower repopulation, 236 
both, CD11b
+
 macrophages and CD14
+ 
monocytes were present in all major organs (Figure 1d).  237 
Infection of these mice with the CCR5-tropic HIV-1 recombinant virus, NL4.3 (BaL env), resulted 238 
in stable viremia, as determined by ultrasensitive qRT-PCR (Figure 2a). Notably, this method 239 
allowed us to observe three phases during infection; an eclipse phase up to day 4 followed by a 240 
burst phase of viral replication before expansion of HIV-1 RNA copies in the plasma of mice from 241 
4 to 9 days before stable peak viremia was reached (Figure 2a). Non-humanized control cohorts 242 
were utilized to demonstrate rapid virological decay in the absence of human cells (Figure 2b). 243 
Strikingly, when comparing the initial decay of HIV-1 RNA in the serum of HIV-1-infected 244 
humanized and non-humanized mice within the first three days of the eclipse phase, the serum HIV-245 
1 RNA half-life was significantly prolonged in mice containing human immune cells (Figure 2c). 246 
At day 22 post-infection, de novo-produced infectious HIV-1 particles were detectable in the serum 247 





 T cells were detectable with a peak at 7 days post-infection before contracting 249 
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This shows that HIV-1 infection in humanized mice can be assessed at very early time-points post 251 
infection and that HIV-1 viremia initially contracts prior to establishing stable serum viremia. 252 
Among the hallmarks of HIV-1 infection is the resulting longitudinal loss of CD4 T cells (28). 253 
Critically, and similar to HIV-1 infection in humans, in this model HIV-1 infection resulted in an 254 
overall reduction of total CD4 T cell counts in peripheral blood and spleen (Figure 2h-j). This 255 
progressively worsened, and in some respects therefore recapitulated progression to AIDS in human 256 
infection (Figure 2h-j). As expected, the infection perturbs the total human leukocyte engraftment 257 
when compared to uninfected mice, leaving the murine CD45-expressing leukocyte population 258 
unchanged (Figure 2k). This demonstrates that the trajectories of HIV-1 infection in humanized 259 
mice bear similarities to those observed in humans. 260 
HIV-1 distinctly suppresses early innate immune activation 261 
Reports from early HIV-1 infection in patients suggest a strong peripheral type I IFN response to 262 
infection (29). However, little information was available on the kinetics and the correlation of 263 
peripheral circulation with lymphoid responses. Thus, it remained unclear as to whether HIV-1 is 264 
able to suppress early host responses. Since HIV-1 infection is associated with immune 265 
hyperactivation (30), we aimed to measure the extent of innate immune activation throughout the 266 
establishment of HIV-1 persistence in humanized mice. To this end, we evaluated the induction of 267 
type I and III IFN at early, intermediate and late time-points. Interestingly, at only 24 hours post 268 
infection, HIV-1 specifically downregulates type I IFN (IFN and IFN) expression in peripheral 269 
blood lymphocytes (Figure 3a-b), while neither of the type III IFNs were expressed (Figure 3c-d). 270 
During the viral eclipse phase up to day 7, HIV-1 infection was associated with marked elevation of 271 
both, type I and type III IFN in peripheral blood lymphocytes (Figure 3a-d). Once HIV-1 infection 272 
was fully established at day 35 post infection, type I and III IFN return to baseline levels in the 273 
peripheral circulation (Figure 3a-d).  274 
To evaluate, what mechanism drives the observed peripheral and splenic production of type I and 275 
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cells or macrophages (Figure 4a, d), we evaluated the presence of pattern recognition receptors 277 
(PRR) able to sense viral RNA on peripheral as well as splenic CD4 T cells (Figure 4b, c) and 278 
macrophages (Figure 4e, f) 10 days following infection with HIV-1. At this point, HIV-1 infection 279 
resulted in a trend towards suppression of Toll-like receptor (TLR)3 protein expression on splenic, 280 
but not peripheral CD4 T cells, whereas peripheral TLR7 and TLR9 protein expression was 281 
elevated after HIV-1 infection of both, CD4 T cells and macrophages (Figure 4b, c, e, f).  282 
To determine, whether this differential TLR profile may be involved in recognition of HIV-1 283 
infection, we performed phosflow pathway analysis of nuclear factor (NF)-B, TANK-binding 284 
kinase (TBK)1 and interferon regulatory factor (IRF)3 in peripheral and splenic CD4 T cells and 285 
macrophages 10 days following infection of humanized mice with HIV-1 (Figure 4g-m). While 286 
splenic CD4 T cells respond to HIV-1 infection by inducing phosphorylation of the NFB subunit 287 
p65 at serine 536, this was not observed in peripheral CD4 T cells or macrophages (Figure 4h, k). 288 
Even though many PRR pathways involve the phosphorylation of TBK1, only macrophages, but 289 
not CD4 T cells exhibited elevated mean fluorescence intensities of phosphorylated TBK1 (Ser172) 290 
(Figure 4i, l). Peripheral but not splenic CD4 T cells additionally showed a trend towards elevated 291 
levels of phosphorylated IRF3 (Ser396) (Figure 4j, m).  292 
Taken together, this indicates that the HIV-1-induced induction of TLR7 and TLR9 expression in 293 
PBMC may be at least partially responsible for peripheral interferon responses.  294 
 295 
HIV-1-associated early immune activation is driven by both, T cells and macrophages in 296 
peripheral, but not lymphoid tissue. 297 
Since HIV-1 infection resulted in a very compartmentalized, early IFN response in PBMC but not 298 
splenic tissue, we assessed the distribution of the respective receptors for type I and III IFN 10 days 299 
following HIV-1 infection by flow cytometry (Figure 5a-d). As expected, the majority of 300 
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IL28RA (Figure 5b, d), whereas only a minority of CD4 T cells expressed predominantly IFNAR1 302 
but not IL28RA (Figure 5a, c).  303 
To assess, which cell populations responded to production of type I and III IFN, we next examined 304 
the level of STAT1 phosphorylation at tyrosine 701, which is indicative of activated JAK/STAT 305 
signaling downstream of type I and III IFN receptors (Figure 5e, f). This showed that macrophages 306 
in PBMC, but not in spleen exhibited activated JAK/STAT signaling in response to HIV-1 307 
infection, indicative of the observed production levels of type I and III IFN (Figure 5e, f). This also 308 
directly correlated with the production of ISG, as exemplified by tetherin/BST2, which was 309 
preferentially induced by HIV-1 infection in CD4 T cells and macrophages in peripheral 310 
circulation, but was not induced in splenic CD4 T cells or macrophages. 311 
This compartmentalized IFN response additionally translated to the selective induction of well-312 
known ISG and HIV-1 restriction factors, including MX2, IFITM1, and IFI44 in PBMC at the peak 313 
of the initial HIV-1 replication burst (Figure 6a-e). Surprisingly, however, both, at the eclipse phase 314 
of infection as well as during late-stage chronic infection, HIV-1 infection suppressed baseline 315 
levels of IFI44 and showed similar trend with SAMHD1 and MX2 expression, indicating that HIV-316 
1 actively shapes its environment. 317 
Taken together, this demonstrates that during early establishment of HIV-1 persistence in this 318 
model, innate immune activation in different compartments is highly dynamic, exhibiting signs of 319 
HIV-1-associated innate immune evasion and repression of expression of key HIV-1 restriction 320 
factors. 321 
 322 
Exogenous type I IFN can override HIV-1-induced repression of restriction factors only in 323 
peripheral circulation 324 
Based on recent experimental studies of SIV infection of macaques, it is possible that type I IFN 325 
accelerates HIV-1 disease progression (31, 32). However, details on the responsiveness of HIV-1 326 
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lacking. To evaluate, whether chronic HIV-1 infection durably suppresses the induction of IFN 328 
responses and HIV-1 restriction factors, we treated HIV-1-infected humanized mice with 1,000 329 
IU/g/day exogenous recombinant (r)IFNα for five consecutive days. This treatment resulted in the 330 
significant reduction of circulating serum HIV-1 RNA levels (Figure 7a, b), indicating that the 331 
elicited inflammatory responses partially inhibited HIV-1 replication. Notably, administration of 332 
rIFN in HIV-1-infected humanized mice exacerbated the observed HIV-1-associated CD4 T cell 333 
depletion, indicating that ISG and proinflammatory cytokines induced by type I IFN contribute to 334 
HIV-1-associated pathogenesis (Figure 7d). 335 
As expected, neither IFNα, IFNβ nor IFN1 mRNA expression was elevated by rIFNα (data not 336 
shown), whereas IFN3, which is itself IFN-stimulated, was induced by 3 log10 at the end of 337 
treatment (Figure 7e, j). rIFNα treatment resulted in the statistically significant increase of both, 338 
SAMHD1 and MX2 in PBMC of HIV-1-infected humanized mice, whereas IFITM1 and IFI44 339 
remained unchanged (Figure 7f-i). Notably, despite a more than 2 log10 induction of IFN3 in 340 
response to rIFN treatment in splenocytes of HIV-1 infected humanized mice, HIV-1 restriction 341 
factors, including SAMHD1, MX2, IFITM1 and IFI44 remained unchanged or were down-342 
regulated by rIFN (Figure 7k-n). This indicates that HIV-1 infection does not result in suppression 343 
of IFN responsiveness in peripheral circulation but induces a compartmentalized interference with 344 
the induction of HIV-1 restriction factors in lymphoid tissue.  345 
 346 
DISCUSSION 347 
Chronic HIV-1 infection is associated with immune hyperactivation. Even though the kinetic of 348 
natural HIV-1 infection has been extensively studied in the past, limited information is available on 349 
very early events following infection. Even though surrogate models for HIV-1 infection have been 350 
used in the past to dissect this, vast genetic differences as well as the presence of the SIV accessory 351 
protein Vpx makes it difficult to directly correlate data from non-human primates with HIV-1 352 
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infection are nearly always limited to peripheral blood, making it impossible to translate findings to 354 
events within lymphatic systems, as well as logistical challenges associated with specimen 355 
collection during the initial phases of HIV-1 infection. 356 
Utilizing humanized mice, we show that HIV-1 infection and subsequent persistence is established 357 
as early as 4 days post infection, as evidenced by comparing HIV-1 serum RNA load to mice 358 
without humanization. This far precedes the significant loss of CD4 T cells, which only becomes 359 
notable after one month of infection.  360 
Strikingly, HIV-1 is able to suppress baseline peripheral IFN and ISG levels very early following 361 
infection, before HIV-1 RNA levels becomes detectable in peripheral circulation. This early 362 
suppression may contribute to the spread of HIV-1-infected cells, since key HIV-1 restriction 363 
factors such as SAMHD1 and MX2 are present in host cells at lower levels. Only one week 364 
following infection, when serum HIV-1 RNA is already detectable, there is a significant peripheral 365 
type I and III IFN signature. However, the lymphatic system, as evidenced by measurements in the 366 
spleen, does not experience type I IFN production and instead, exhibits a type III IFN signature. 367 
This absence of splenic type I IFN responses coincides with a trend towards reduced expression of 368 
the RNA sensor TLR3 on splenic CD4 T cells. Additionally, in contrast to peripheral CD4 T cells, 369 
HIV-1 infection does not induce expression of TLR7 in splenic CD4 T cells or macrophages. This 370 
suggests a skewing of HIV-1-induced signaling towards pro-inflammatory NFB, rather than IFN-371 
inducing IRF3 signaling in T cells and macrophages in the spleen. This could contribute to the 372 
pyroptosis-induced CD4 T cell loss characteristic during HIV-1 infection (33). In contrast, 373 
peripheral CD4 T cells show a trend towards increased phosphorylation and activation of IRF3. 374 
This may, at least in part, explain the observed differential and compartmentalized type I and III 375 
IFN production. 376 
This is furthermore underpinned by the absence of an ISG response in the spleen, whereas multiple 377 
ISG and HIV-1 restriction factors are upregulated on the mRNA and protein level in the peripheral 378 
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expansion in the near absence of restriction by host factors. Notably, even after the early peripheral 380 
induction of IFN and ISG responses, persistence of HIV-1 is associated with reduced expression of 381 
select ISG and restriction factors in peripheral blood, which further underpins the ability of HIV-1 382 
to evade host restriction. This suppression of key HIV-1 restriction factors may render the host 383 
more susceptible to systemic dissemination of HIV-1 infection. 384 
Despite this evasion mechanism, PBMC retain their responsiveness to type I IFN, as exogenous 385 
treatment with recombinant IFN results in the induction of SAMHD1, IL28b and MX2. However, 386 
splenic cells of HIV-1-infected humanized mice, upon treatment with recombinant IFN display an 387 
inverse response to type I IFN, resulting in repressed restriction factor expression. In particular 388 
SAMHD1 is significantly downregulated after IFN treatment, suggesting that HIV-1 may have 389 
evolved means to facilitate its dissemination in lymphatic tissue despite immune activation. This 390 
cannot be explained by a potential hurdle for rIFN to penetrate to the spleen upon exogenous 391 
administration, since IL28b, which itself is IFN-stimulated is readily detectable in the spleen. 392 
Surprisingly, another study using BLT mice, which exhibit a more functional adaptive immune 393 
system with the T cells’ ability to mount protective antigen-specific immune responses has 394 
demonstrated that CD4 T cell loss is delayed and that MX1 levels are chronically elevated (34). We 395 
observe very similar elevations of MX1, however, MX1, in contrast to MX2 has not been shown to 396 
restrict HIV-1 infection and a comparative analysis in humanized mice has not been previously 397 
performed (35). Thus, the different kinetics of CD4 T cell loss may be due to antigen-specific T cell 398 
responses against HIV-1 infection releasing IFN. Additionally, another study has demonstrated 399 
that blocking type I IFN signaling results in T cell recovery during HIV-1 infection, supporting the 400 
notion that type I IFN might be associated with disease progression (36). 401 
Taken together, we show that IFN and ISG responses during acute HIV-1 infection in humanized 402 
mice are highly dynamic, exhibiting evidence for early viral suppression and peak recognition of 403 
HIV-1 by the innate immune system during the initial burst of HIV-1 replication. The trend 404 
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additionally contribute to the lack of HIV-1 RNA recognition. Since most of the initially induced 406 
HIV-1 restriction factors are returning to baseline or below baseline expression during chronic HIV-407 
1 infection, this could explain why HIV-1 is largely uncontrolled at later stages during infection. 408 
The induction of other ISGs without direct antiretroviral action could potentially result from other 409 
activation pathways and do not necessarily reflect the responses of ISGs in general. Indeed, 410 
CXCL10, which is commonly used as marker for IFN stimulation and was shown to be elevated in 411 
untreated HIV-1-infected patients (37) was recently shown to be induced via TLR7/9 activation 412 
(38), rather than through JAK/STAT signaling. Most strikingly, the observed very early suppression 413 
of IFN and ISG responses in vivo has not been observed thus far. This early interference of 414 
pathogen sensing and IFN activation by HIV-1 may function as a viral strategy to establish an early 415 
reservoir and to eliminate restriction factor roadblocks preventing the establishment of HIV-1 416 
persistence. The mechanism, by which HIV-1 infection results in the transcriptional down-417 
regulation or destabilization of IFN mRNA remains elusive. However, many host proteins as well 418 
as viral accessory proteins (e.g. Vpr) are directly packaged within the HIV-1 virion and could 419 
contribute to this early down-modulation of the IFN system. This suggests that careful future 420 
analysis of single cell transcriptional responses in vitro and in vivo is required to delineate, which 421 
restriction factors are present and functional in HIV-1-infected as well as –uninfected bystander 422 
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 548 
Figure legends 549 
 550 
Figure 1. Humanized mice engraft with human cells in all major organs.  551 
(a) Representative flow cytometry plots depicting human cell populations in humanized (HIS) NRG 552 
mice in both the peripheral blood and spleen. (b) Percentage of human cell engraftment in HIS mice 553 
in the PBMC, spleen, brain, lung and liver tissue. Engraftment is depicted as the percentage of 554 
human CD45+ cells in the total leukocyte population (e.g. human CD45 and mouse CD45). (c) 555 
Frequency of CD3+ T cells, CD19+ B cells and lineage negative cells (Lin
-
, CD3-CD19-) in 556 
PBMC, spleen, brain, lung and liver. (d) Frequency of CD4+ and CD8+ T cells (within the CD3+ 557 
cell population) and CD14+ monocytes and CD11b+ macrophages (within the lineage negative 558 
population) as depicted in 1c. Data shown are from 12 humanized NRG mice reconstituted with 3 559 
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 561 
Figure 2. HIV-1 results in distinct phases of infection in humanized mice. 562 
(a) Serum HIV-1 RNA kinetic in humanized NRG mice following infection with 2.1 IU RT NL4.3 563 
(BaL env) as measured by two-step qRT-PCR. Data shown are mean ± SEM (blue circles) of 12 564 
mice per cohort as well as individual animals (grey lines). Numbers indicate eclipse (1), burst (2) 565 
and chronic (3) phases of infection. (b) Serum HIV-1 RNA kinetic in non-humanized NRG mice 566 
following infection with 2.1 IU RT NL4.3 (BaL env) as measured by two-step qRT-PCR. Data 567 
shown are mean ± SEM (blue circles) of 7 mice per cohort as well as individual animals (grey 568 
lines). (c) Serum HIV RNA half-life calculated between day 1 and 3 of infection of HIS-NRG or 569 
NRG mice by one phase exponential decay least squares fitting. (d) HIV-1 infectious units in 570 
plasma isolated from HIV-1-infected humanized mice at day 22-post infection as measured by 571 
GHOST cell titration. (e) Representative flow cytometry plots of CD3+ CD4+ p24+ T cells in both 572 
HIV-1 infected and uninfected HIS mice in peripheral circulation and splenic tissue. (f, g) 573 
Percentage of HIV-1-infected CD3+ CD4+ p24+ cells observed in (f) PBMC and (g) splenic tissue 574 
at days 10 and 35-post HIV-1 infection as determined by flow cytometry and analysed by Wilcoxon 575 
matched-pairs signed rank test with Bonferroni corrections. (h) Longitudinal CD4 T cell loss in 576 
peripheral blood of HIV-1-infected HIS mice. Data shown are mean ± SEM (blue circles) of 5 mice 577 
per cohort as well as individual animals (grey lines). Statistical significance was determined 578 
between mock-infected and HIV-1-infected humanized mice at day 49 post infection using Mann-579 
Whitney with Bonferroni corrections. (i, j) Absolute CD4 T cell loss in (i) PBMC and (j) spleen of 580 
HIS mice 35 days following infection with 2.1 IU RT NL4.3 (BaL env). Data shown are mean ± 581 
SEM (blue circles) of 19 and 9 mice per cohort, respectively, analysed by Mann-Whitney test using 582 
Bonferroni corrections. (k) Cell count of human and mouse CD45 leukocytes in HIS mice before 583 
and 35 days after HIV-1 infection. Data shown are mean ± SEM of 9 uninfected and 10 HIV-1-584 
infected mice Wilcoxon matched-pairs signed rank test with Bonferroni corrections. For all 585 
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 587 
Figure 3. HIV-1 induces a compartmentalized interferon response in humanized mice. (a-d) 588 
mRNA expression of (a) IFNα, (b) IFNβ, (c) IFNλ3 and (d) IFNλ1 in peripheral blood lymphocytes 589 
and splenic lymphocytes isolated from HIV-1-infected humanized mice at 1, 7 and 35 days and 10 590 
and 35, respectively. Statistical significance was determined between mock and HIV-1 infected 591 
mice using Mann-Whitney test with Bonferroni corrections. Data shown are mean ± SEM of 5 mice 592 
per cohort for peripheral lymphocytes and 3 uninfected and 4 HIV-1-infected mice for splenic 593 
lymphocytes.  594 
 595 
Figure 4. HIV-1 infection regulates TLR expression and induces differential pattern 596 
recognition in T cells and macrophages. (a) Total human CD4 T cell count in PBMC and spleen 597 
of uninfected and HIV-1-infected humanized mice 10 days following infection as determined by 598 
flow cytometry. (b) Representative flow cytometry plots and (c) combined protein expression of 599 
TLR3, TLR7, TLR8 and TLR9 in human CD4 T cells from PBMC and spleen of uninfected and 600 
HIV-1-infected human CD4 T cells 10 days following infection as determined by flow cytometry 601 
and analysed by Mann-Whitney test with Bonferroni corrections. (d) Total human CD33+ 602 
macrophage counts in PBMC and spleen of uninfected and HIV-1-infected humanized mice 10 days 603 
following infection as determined by flow cytometry. (e) Representative flow cytometry plots and 604 
(f) combined protein expression of TLR3, TLR7, TLR8 and TLR9 in human CD33+ macrophages 605 
from PBMC and spleen of uninfected and HIV-1-infected human CD4 T cells 10 days following 606 
infection as determined by flow cytometry and analysed by Mann-Whitney test with Bonferroni 607 
corrections.  (g) Representative flow cytometry plots and (h-m) combined frequency and mean 608 
fluorescence intensity of protein phosphorylation of (h, k) p65 Ser536 (NFB), (i, l) pTBK1 Ser172 609 
and (j, m) pIRF3 Ser396 in (h-j) human CD4 T cells and (k-m) human CD33+ macrophages in 610 
PBMC and spleen of uninfected and HIV-1-infected humanized mice 10 days following infection as 611 
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Data shown are mean ± SEM of 6 uninfected and 7 HIV-1-infected mice. For all statistical tests, a p 613 
value of <0.05 was deemed significant. 614 
 615 
 616 
Figure 5. HIV-1 infection induces JAK/STAT signaling in human T cells and macrophages in 617 
humanized mice. (a, b) Mono- and co-expression of IFNAR1 and IL28RA on (a) human CD4 T 618 
cells and (b) human CD33 macrophages in PBMC and spleen of uninfected and HIV-infected 619 
humanized mice 10 days following infection. (c, d) Phosphorylation of STAT1 (Tyr701) in (c, d) 620 
Expression of IFNAR1 and/or IL28RA on (c) CD4 T cells and (d) macrophages in PBMC and 621 
spleen of uninfected and HIV-1-infected humanized mice 10 days following infection as 622 
determined by flow cytometry. (e, f) Frequency and mean fluorescence intensity of phosphorylated 623 
STAT1 at tyrosine 701 in (e) human CD4 T cells and (f) macrophages in PBMC and spleen of 624 
uninfected and HIV-infected humanized mice 10 days following infection as determined by flow 625 
cytometry and analysed by Mann-Whitney test with Bonferroni corrections. (g, h) Cell surface 626 
expression of BST2/tetherin on (g) human CD4 T cells and (h) macrophages 10 days following 627 
infection as determined by flow cytometry and analysed by Mann-Whitney test with Bonferroni 628 
corrections. Data shown are mean ± SEM of 6 uninfected and 7 HIV-1-infected mice. For all 629 
statistical tests, a p value of <0.05 was deemed significant. 630 
 631 
 632 
Figure 6. Dynamic gene expression profiles of key HIV-1 restriction factors indicates early 633 
expression is perturbed 634 
(a-f) mRNA expression of (a) SAMHD1, (b) MX1, (c) MX2, (d) IFITM1, and (e) IFI44 in 635 
peripheral blood lymphocytes and splenic lymphocytes isolated from HIV-1-infected humanized 636 
mice at 1, 7 and 35 days and 10 and 35, respectively. Data shown are mean ± SEM of 5 mice per 637 
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lymphocytes. Statistical significance was determined for unpaired mock and HIV-1 infected mice 639 
using Mann-Whitney test, paired HIV-1 infected mice between days 1,7, and 35 using Wilcoxon 640 
matched-pairs signed rank test, both with Bonferroni corrections. For all statistical tests, a p value 641 
of <0.05 was deemed significant. 642 
 643 
Figure 7. HIV-infected peripheral but not splenic cells retain their responsiveness to 644 
exogenous interferon. (a) Longitudinal serum HIV-1 RNA copies in humanized mice upon 645 
treatment with 1,000 IU/g rIFN intraperitoneally for 5 consecutive days (red shading). (b) Serum 646 
HIV RNA copies in untreated and rIFN-treated mice 5 days after treatment as determined by HIV 647 
qRT-PCR and analysed by Mann-Whitney test with Bonferroni corrections. (c) Number of p24-648 
positive CD4 T cells in PBMC and spleen of untreated and rIFN-treated mice 5 days after 649 
treatment as determined by flow cytometry. (d) CD4 T cell count in PBMC and spleen of untreated 650 
and rIFN-treated mice 5 days after treatment as determined by flow cytometry and analysed by 651 
Mann-Whitney test with Bonferroni corrections. (e-n) mRNA expression of (e, j) IL28b, (f, k) 652 
SAMHD1, (g, l) MX2, (h, m) IFITM1 and (i, n) in (e-i) PBMC and (j-n) spleen of untreated and 653 
rIFN-treated mice 5 days after treatment as determined by qRT-PCR and analysed by Mann-654 
Whitney test with Bonferroni corrections. Data shown are mean ± SEM of 5 mice per cohort and 655 
for all statistical tests, a p value of <0.05 was deemed significant. 656 
 657 
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Tables 659 
 660 
Table 1. Humanized mouse cohort information 661 
 662 
 Mock infection HIV infection Total 
Number of mice 41 55 96 
Animal sex [m/f] 18/23 21/34 96  
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